We are thrilled to announce we have reached our target of raising £25m for our new Centre for Cancer Immunology. Thanks to an overwhelming response from donors, fundraisers and supporters, across the UK and internationally, we have reached our campaign goal six months ahead of schedule.
This World Cancer Day, please join us in supporting our Centre for Cancer Immunology by wearing white and sharing your photos on social media using #WearingWhite 1-4 February 2018. You’ll be helping us spread the word about our life-saving research and our new world-leading Centre.
We are delighted to announce that we have now raised £24m for our new Centre – leaving just £1m to go to reach the final target by next summer! Thank you to all our supporters for helping us end this year on such a high.
A University of Southampton study has found that combining two different immunotherapy treatments could dramatically improve lymphoma survival.
Dr Sean Lim, who led the study, said: “By combining two specific antibodies we’ve increased the ability of the immune system to destroy cancer cells. It’s very exciting to see that this drug combination has an impact on survival.”
An immunology discovery from the laboratories at the University of Southampton has now been shown to improve the outcomes of a common type of blood cancer in patients: follicular lymphoma, a type of non-Hodgkin lymphoma. Julie Davis, pictured here, took part in the trial at Southampton and is now in full remission.
We are very excited to announce that our campaign is now entering its final fundraising phase thanks to a £2m gift! The generous donation, given by a Guernsey resident, means we are now in touching distance of our £25m target with the total now standing at £23.8m.
September is National Blood Cancer Awareness Month. We have much to celebrate at the University of Southampton as our scientists are, for the first time, to trial a new experimental drug, in combination with immunochemotherapy, in certain patients with the most common type of fast-growing non-Hodgkin lymphoma, a type of blood cancer.
We are delighted that international rock sensation Coldplay have donated to our Centre for Cancer Immunology. The band chose the campaign through the close links drummer Will Champion has with both Southampton and the University. Will grew up in Southampton and his parents were both senior academics at the University before his mother sadly passed away from cancer in 2000. The donation moves the campaign total to £21.6m.
Researchers from the University of Southampton have identified why some people may become resistant to rituximab, a common type of immunotherapy used in treating lymphoma (a type of blood cancer), and how an immune response stimulating drug called a ‘STING agonist’ could overcome this, paving the way for improved patient outcomes. The pioneering research is being led by the University’s Dr Stephen Beers, pictured here, in conjunction with Professor Mark Cragg.
Scientists have discovered a new type of immune cell that could predict which lung cancer patients will benefit most from immunotherapy treatment, according to a University of Southampton study published in Nature Immunotherapy. Christian Ottensmeier, Professor of Experimental Medicine at the University said: “These are hugely exciting results. For the first time we have a real indication of who might benefit from a particular drug before we make treatment decisions.”